Génome Québec is proud to recognize a major investment by AmorChem for Acute Myeloid Leukemia
AmorChem investment of $1.5 million will serve to develop new diagnostic and prognostic tools for acute myeloid leukemia (AML) patients to predict how they should be treated based on the…